nrx-1074
Small moleculeexperimental
Clinical trial activity
6 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2013 (NCT01856556)
Timeline
Indications
Mechanism of action
- Glutamate [NMDA] receptorPARTIAL AGONIST
Glutamate [NMDA] receptor partial agonist
Partial agonist of the glycin-site on GRIN1-subunits, preferentially modulates NR2B-containing NMDAR receptor complexes.
- Glutamate receptor ionotropic, NMDA 1 (GRIN1) ↗
- Glutamate receptor ionotropic, NMDA 2A (GRIN2A) ↗
- Glutamate receptor ionotropic, NMDA 2B (GRIN2B) ↗
- Glutamate receptor ionotropic, NMDA 2D (GRIN2D) ↗
- Glutamate receptor ionotropic, NMDA 3B (GRIN3B) ↗
- Glutamate receptor ionotropic, NMDA 2C (GRIN2C) ↗
- Glutamate receptor ionotropic, NMDA 3A (GRIN3A) ↗
- Glutamate (NMDA) receptor subunit zeta 1
- Glutamate [NMDA] receptor subunit epsilon 1
- Glutamate [NMDA] receptor subunit epsilon 2
- Glutamate [NMDA] receptor subunit 3A
- Glutamate [NMDA] receptor subunit epsilon 4
- Glutamate [NMDA] receptor subunit epsilon 3
- Glutamate NMDA receptor; GRIN1/GRIN2B
- Glutamate NMDA receptor; GRIN1/GRIN2A
- Ionotropic glutamate receptor NMDA 1/2C
- Ionotropic glutamate receptor NMDA 1/2D
- Glutamate NMDA receptor; GRIN1/GRIN2A/GRIN2B
- Glutamate receptor ionotropic, NMDA 1/2C/3B
Chemistry & pharmacology
Loading structure…
SMILES
C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@@]1(Cc1ccccc1)C(=O)N[C@H](C(N)=O)[C@@H](C)O- Mol. weight
- 503.6 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3989872 ↗
- ChEMBLCHEMBL3545230 ↗
Also known as
- nrx-1074
- nrx-1074
- nrx-1074
- nrx-1074
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06400121 | Phase 2 | Oct 28, 2024 | Gate Neurosciences, Inc, University of Pittsburgh |
| NCT05597241 | Phase 1 | Oct 15, 2022 | Gate Neurosciences, Inc |
| NCT02603458 | Phase 2 | Nov 9, 2015 | Naurex, New York University |
| NCT02366364 | Phase 1 | Feb 1, 2015 | Chicago Research Center, Inc., Naurex |
| NCT02067793 | Phase 2 | Mar 1, 2014 | Allergan, Naurex |
| NCT01856556 | Phase 1 | May 1, 2013 | Lotus Clinical Research, Naurex |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Naurex | For profit | 4 | 3 | 2 | 2013 |
| Gate Neurosciences, Inc | For profit | 2 | 1 | 2 | 2022 |
| Allergan | For profit | 1 | 0 | 1 | 2014 |
| Chicago Research Center, Inc. | For profit | 1 | 0 | 1 | 2015 |
| Lotus Clinical Research | For profit | 1 | 0 | 1 | 2013 |
| New York University | Academic/Hospital | 1 | 1 | 1 | 2015 |
| University of Pittsburgh | Academic/Hospital | 1 | 1 | 1 | 2024 |
7 organizations
Page 1 / 1